The loss of tumor suppressor genes such as PTEN in chromosome 10, in particular, represent a well described mechanism of tumor evolution, and in recent years, many targeted therapies, such as the use of repurposed viruses, small-molecules inhibitors and monoclonal antibodies, have been focused on either increasing PTEN expression or blocking the pathways it naturally downregulates, with mostly discouraging outcomes. This evidence concerns the gene PTEN and neoplasm.